Meda acquires Antula with well-known brands such as SB12, Anti, Zyx, Eeze and Inside

Meda acquires Antula with well-known brands such as SB12, Anti, Zyx,
Eeze and Inside

•  Consistent step in Meda's OTC strategy

       - Sales of about SEK 500 million with strong growth in the Nordic
markets

       - Well-established brands that will be launched internationally

       - A strong pipeline of 3-4 new products that can be launched
annually

   •  Purchase price and time table

       - Purchase consideration of SEK 1,800 million (on a debt-free
basis)

       - Financed using existing credit facilities

       - The acquisition is expected to be completed within a couple of
months

Meda has signed an agreement to acquire Antula with well-known brands
such as SB12, Anti, Zyx, Becur, Ac3, Lactal Balans, Eeze, Nalox, and
Inside. Antula is a growing company that concentrates on
prescription-free (OTC) products. In five years, Antula has built strong
brandnames and generated sales of some SEK 500 million just in the
Nordics. Its integration with Meda opens doors to an international
marketplace and broadens its potential through Meda's OTC organization.

Meda has expressed its ambition to build a strong position in OTC
products, an area that it has continually expanded in recent years.
Antula's and Meda's OTC products will together make up over 20% of
Meda's total sales.

The acquisition of Antula offers Meda clear growth opportunities, partly
through Meda and Antula's existing products, and partly through Antula's
pipeline that consists of three to four new products annually. Antula is
established in the Nordics with its own organization. Through the
integration with Meda, several of the products will have potential to
become internationally strong brands.

“We are pleased to welcome the Antula team to Meda. They have
demonstrated their considerable expertise in consumer marketing and we
are looking forward to an exciting future together," said Anders Lönner,
CEO of Meda AB.

”I'm delighted that we have found a perfect home for Antula within Meda.
This is the right step so we can unlock the value of Antula's products
on an international base with Meda's organization. Antula's pipeline
also offers Meda an additional growth opportunity”, said Barry Clare,
founder of Healthcare Brands International, Antula's current owner.

The acquisition price for Antula is SEK 1,800 million on a debt-free
basis. The acquisition will be financed using Meda's existing credit
facilities. The transaction is subject to standard closing requirements
and the approval of the competition authorities. The acquisition of
Antula is expected to be completed within a couple of months.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46
709-458 878